ATE446971T1 - Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese - Google Patents

Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese

Info

Publication number
ATE446971T1
ATE446971T1 AT02766246T AT02766246T ATE446971T1 AT E446971 T1 ATE446971 T1 AT E446971T1 AT 02766246 T AT02766246 T AT 02766246T AT 02766246 T AT02766246 T AT 02766246T AT E446971 T1 ATE446971 T1 AT E446971T1
Authority
AT
Austria
Prior art keywords
synthesis
oligomer conjugates
polypeptide
proinsulin
insulin
Prior art date
Application number
AT02766246T
Other languages
English (en)
Inventor
Richard Soltero
Balasingham Radhakrishnan
Nnochiri Ekwuribe
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/036,744 external-priority patent/US6913903B2/en
Application filed by Biocon Ltd filed Critical Biocon Ltd
Application granted granted Critical
Publication of ATE446971T1 publication Critical patent/ATE446971T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02766246T 2001-09-07 2002-09-06 Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese ATE446971T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31819701P 2001-09-07 2001-09-07
US10/036,744 US6913903B2 (en) 2001-09-07 2001-12-21 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US34946202P 2002-01-18 2002-01-18
PCT/US2002/028428 WO2003022996A2 (en) 2001-09-07 2002-09-06 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Publications (1)

Publication Number Publication Date
ATE446971T1 true ATE446971T1 (de) 2009-11-15

Family

ID=27365090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766246T ATE446971T1 (de) 2001-09-07 2002-09-06 Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese

Country Status (16)

Country Link
EP (1) EP1430082B1 (de)
JP (1) JP4318546B2 (de)
AR (1) AR036449A1 (de)
AT (1) ATE446971T1 (de)
AU (1) AU2002329989A1 (de)
CY (1) CY1110640T1 (de)
DE (1) DE60234198D1 (de)
DK (1) DK1430082T3 (de)
ES (1) ES2333781T3 (de)
MY (1) MY127575A (de)
PE (1) PE20030536A1 (de)
PT (1) PT1430082E (de)
SA (1) SA02230453B1 (de)
SI (1) SI1430082T1 (de)
UY (1) UY27439A1 (de)
WO (1) WO2003022996A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1569683B1 (de) 2002-11-26 2010-03-03 Biocon Limited Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
MX2007000883A (es) * 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
EP1893240A2 (de) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmukosale abgabe von peptid-derivaten
CN101291952B (zh) 2005-10-13 2016-02-03 拜奥康有限公司 制备胰岛素缀合物的方法
EP2049149B1 (de) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylierte verlängerte insuline
EP2404934A1 (de) 2006-09-22 2012-01-11 Novo Nordisk A/S Proteaseresistente Insulinanaloga
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
BR112020025924A2 (pt) * 2018-06-18 2021-03-23 Biocon Limited método e uso de controle de níveis de glicose pós-prandial em um indivíduo
CN113087623A (zh) * 2021-04-13 2021-07-09 苏州昊帆生物股份有限公司 一种8-溴辛酸乙酯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4431740A (en) * 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
AU2002329989A1 (en) 2003-03-24
EP1430082A2 (de) 2004-06-23
PT1430082E (pt) 2010-01-15
SI1430082T1 (sl) 2010-02-26
SA02230453B1 (ar) 2008-02-05
DK1430082T3 (da) 2010-01-18
JP2005502353A (ja) 2005-01-27
WO2003022996A3 (en) 2003-12-31
WO2003022996A2 (en) 2003-03-20
CY1110640T1 (el) 2015-04-29
DE60234198D1 (de) 2009-12-10
MY127575A (en) 2006-12-29
EP1430082A4 (de) 2004-11-24
PE20030536A1 (es) 2003-07-03
JP4318546B2 (ja) 2009-08-26
AR036449A1 (es) 2004-09-08
EP1430082B1 (de) 2009-10-28
ES2333781T3 (es) 2010-03-01
UY27439A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
ATE446971T1 (de) Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese
DE50212077D1 (de) Piezoelektrisches bauelement und verfahren zu dessen herstellung
DE60114415D1 (de) Niob- und tantal-pulver und verfahren zu deren herstellung
DE60200412D1 (de) Polyhydroxyalkanoat und Verfahren zu dessen Herstellung, und Omega-(2-Thienylsulfanyl)alkansäure und Verfahren zu deren Herstellung
DE60124291D1 (de) Extrusions-blasgeformter zusammendrückbarer behälter und verfahren zu dessen herstellung
DE60117573D1 (de) Verschiedenartig gehärtete materialen und verfahren zur deren herstellung
DE60305105D1 (de) Aluminiumbeschichtetes Bauteil und Verfahren zu dessen Herstellung
DE60134016D1 (de) Wabenstruktur und wabenfilter und verfahren zu deren herstellung
AT501583B8 (de) Dualband-antenne und verfahren zu ihrer herstellung
DE60207327D1 (de) Spuleneinheit und Verfahren zu deren Herstellung
EP1613592A4 (de) Hydroxansäureverbindungen und verfahren zu deren anwendung
ATE288911T1 (de) Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
DE60111904D1 (de) Biosensor und verfahren zu dessen herstellung
DE50214272D1 (de) Piezoelektrisches bauelement und verfahren zu dessen herstellung
DE60110543D1 (de) Verbundwerkstoff und Verfahren zu deren Herstellung
DE60226707D1 (de) Kunsthaare und verfahren zu deren herstellung
DE60318167D1 (de) Arzneiform und Verfahren zu ihrer Herstellung
DE60235706D1 (de) Photochrome bis-naphtopyranverbindungen und verfahren zu deren herstellung
DE60238570D1 (de) Piezoelektrischer Oszillator und Verfahren zu dessen Herstellung
DE60200495D1 (de) Polyethylenglykol und Verfahren zu dessen Herstellung
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
DE60308125D1 (de) Verbinder und Verfahren zu dessen Herstellung
DE50206164D1 (de) Substituierte indole verfahren zu deren herstellung und deren verwendung zur schmerzbekämfung
ATE522205T1 (de) Testosteronhaltiges transdermales therapeutisches system und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1430082

Country of ref document: EP